Crinetics Pharmaceuticals, Inc.

CRNX • Biotechnology

$84.95

— 0.00 (0.00%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$8.97B

Growth

7.6%

Cash Flow

0/5

Trend

Negative

Evidence

Positive revenue growth · 30.7%Manageable debt level · 0.05Healthy liquidity · 12.32Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 1:42 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$84.95

Change0.00%

Shares Out105.56M

Market Cap$8.97B

Enterprise Value$7.81B

52W Range25.83 - 84.06

Beta0.13

P/E-17.88

P/S212.72

P/B7.52

P/FCF-21.09

EV/Sales185.23

Price$84.95

Change0.00%

Shares Out105.56M

Market Cap$8.97B

Enterprise Value$7.81B

52W Range25.83 - 84.06

Beta0.13

P/E-17.88

P/S212.72

P/B7.52

P/FCF-21.09

EV/Sales185.23

EV/EBITDA-14.30

EV/FCF-18.37

Earnings Yield-5.59%

FCF Yield-4.74%

Dividend Yield0.00%

Gross Margin86.02%

Oper. Margin-67.15%

Profit Margin-60.46%

Debt/Eq0.05

Current Ratio12.32

Quick Ratio12.30

Revenue 5Y7.57%

Target$84.86

Target Upside-0.11%

Target Median$85.00

Target Range84.00 - 85.00

Volume49.63K

Avg Volume3.74M

EPS Surprise-0.01

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

43/100

Why this score▼

Positive revenue growth · 30.7%Manageable debt level · 0.05Healthy liquidity · 12.32Weak profitability

Analyst view

Analyst sentiment and price target

CRNX

Analyst sentiment

Based on 21 analyst votes · 2026-09-05

81/100

Bullish

Hold

Bearish

Price Target

2026-08-06

Low

$84.00

Mean

$84.86

Median

$85.00

High

$85.00

Company Overview

IPO: 7/18/2018

Industry: Biotechnology

P/B i: 7.52

Debt / Equity i: 0.05

Operating Margin: -6714.77%

Net Margin: -6046.22%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.05

Current Ratio: 12.32

Quick Ratio: 12.30

Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected

Vivaldi Coelho Rogerio

Transaction: 07/02/2026

SELL

Change

-3,000

Price

$40.00

Filing

07/07/2026

Type

SELL

Okey Stephanie

Transaction: 06/18/2026

BUY

Change

+9,730

Price

$35.87

Filing

06/22/2026

Type

BUY

Okey Stephanie

Transaction: 06/18/2026

BUY

Change

+5,925

Price

Not reported

Filing

06/22/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Vivaldi Coelho Rogerio	SELL	-3,000	$40.00	07/02/2026	07/07/2026
Okey Stephanie	BUY	+9,730	$35.87	06/18/2026	06/22/2026
Okey Stephanie	BUY	+5,925	Not reported	06/18/2026	06/22/2026
WIERENGA WENDELL	BUY	+9,730	$35.87	06/18/2026	06/22/2026
WIERENGA WENDELL	BUY	+5,925	Not reported	06/18/2026	06/22/2026
Bedrosian Camille L	BUY	+9,730	$35.87	06/18/2026	06/22/2026
Bedrosian Camille L	BUY	+5,925	Not reported	06/18/2026	06/22/2026
Vivaldi Coelho Rogerio	BUY	+9,730	$35.87	06/18/2026	06/22/2026
Vivaldi Coelho Rogerio	BUY	+5,925	Not reported	06/18/2026	06/22/2026
Nichols Weston	BUY	+9,730	$35.87	06/18/2026	06/22/2026
Nichols Weston	BUY	+5,925	Not reported	06/18/2026	06/22/2026
Fust Matthew K	BUY	+9,730	$35.87	06/18/2026	06/22/2026
Fust Matthew K	BUY	+5,925	Not reported	06/18/2026	06/22/2026
Deardorf Caren	BUY	+9,730	$35.87	06/18/2026	06/22/2026
Deardorf Caren	BUY	+5,925	Not reported	06/18/2026	06/22/2026
Okey Stephanie	SELL	-608	$36.22	06/17/2026	06/18/2026
Struthers Richard Scott	SELL	-111,100	Not reported	05/29/2026	06/02/2026
Knight Jeff E.	SELL	-9,624	$20.02	04/08/2026	04/10/2026
Knight Jeff E.	SELL	-85,163	$40.10	04/08/2026	04/10/2026
Struthers Richard Scott	SELL	-8,785	$37.77	03/16/2026	03/18/2026

About the Company

Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

Source - link

Peers

ACAD AKRO DYN IMVT KYMR NAMS PRAX SLNO VKTX XENE

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company's continued growth and diversification. Completion of Acquisition of Crinetic.

Business Wire

BlackRock Inc. Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNX

BlackRock Inc. purchased a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 9,758,938 shares of the company's stock, valued at approximately $365,179,000. BlackRock Inc. owned approximately 9.20% of

Defense World

AWM Investment Company Inc. Invests $3.18 Million in Crinetics Pharmaceuticals, Inc. $CRNX

AWM Investment Company Inc. bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) in the quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 85,000 shares of the company's stock, valued at approximately $3,181,000. AWM Investment Company Inc. owned approximately 0.08% of Crinetics Pharmaceuticals

Defense World

Deutsche Bank AG Invests $10.62 Million in Crinetics Pharmaceuticals, Inc. $CRNX

Deutsche Bank AG purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) during the quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 283,727 shares of the company's stock, valued at approximately $10,617,000. Deutsche Bank AG owned about 0.27% of

Defense World

Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?

Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026

GuruFocus

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	-1.22	-1.23	-0.01
2026-02-26	-1.37	-1.29	0.08
2025-11-06	-1.27	-1.38	-0.11
2025-08-07	-1.13	-1.23	-0.1
2025-05-08	-0.99	-1.04	-0.05
2025-02-27	-0.92	-0.88	0.04
2024-11-12	-0.91067	-0.96	-0.04933
2024-08-08	-0.86	-0.94	-0.08
2024-05-09	-0.84	-0.93	-0.09
2024-02-28	-0.89	-0.9	-0.01
2023-11-07	-0.89	-1.01	-0.12
2023-08-08	-0.85	-0.94	-0.09